Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11198
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc is a drug development company that develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcinoma caused by hormone abnormalities. Its pipeline products include ATR-101 and MLE4901. Millendo Therapeutics’ MLE4901 product is used for the treatment of polycystic ovary syndrome and MLE4901 is a neurokinin 3 receptor antagonist that helps decrease gonadotropin releasing hormone hyperpulsatility and luteinizing hormone pulse frequency. The company’s ATR-101 is used to treat ACC congenital adrenal hyperplasia and endogenous cushing’s syndrome. It also provides treatments for endocrine diseases caused by hormone dysregulation of medications exist. Millendo Therapeutics is headquartered in Ann Arbor, Michigan, the US.

Millendo Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
Merger 15
OvaScience to Merge with Millendo Therapeutics 15
Licensing Agreements 17
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 17
Acquisition 18
Millendo Therapeutics Acquires Alize Pharma 18
Millendo Therapeutics Inc – Key Competitors 19
Millendo Therapeutics Inc – Key Employees 20
Millendo Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Nov 14, 2018: Millendo Therapeutics names Louis Arcudi III as Chief Financial Officer and Michael Yeh as Vice President of Medical Affairs 22
Sep 25, 2018: Millendo Therapeutics names Habib Dable as Board Director 23
Jun 28, 2018: Millendo Therapeutics Names Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions 24
Apr 11, 2017: Millendo Therapeutics Appoints Mary Lynne Hedley, Ph.D. and Carole Nuechterlein, J.D. to Board of Directors 25
Clinical Trials 26
Sep 17, 2018: Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH 26
Mar 07, 2018: Millendo Therapeutics Announces Data Presentation for Nevanimibe at ENDO 2018 27
Nov 08, 2017: Millendo Therapeutics Announces Positive Topline Phase 2 Results of ATR-101 in Classic Congenital Adrenal Hyperplasia 28
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome 29
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
OvaScience to Merge with Millendo Therapeutics 15
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 17
Millendo Therapeutics Acquires Alize Pharma 18
Millendo Therapeutics Inc, Key Competitors 19
Millendo Therapeutics Inc, Key Employees 20

List of Figures
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OJSC Rosneft Oil Company:企業の戦略・SWOT・財務分析
    OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report Summary OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Velvet Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Velvet Energy Ltd (Velvet Energy) is an oil and gas exploration company that explores and develops oil and liquid-rich natural gas from its assets. The company’s exploration and development operation assets are located in Deep Basin in West-Central Alberta. It produces 17,000 barrels of oil …
  • HORNBACH-Baumarkt-AG (HBM):企業の財務・戦略的SWOT分析
    HORNBACH-Baumarkt-AG (HBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NeoGenomics Inc (NEO)-医療機器分野:企業M&A・提携分析
    Summary NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immuno …
  • ImpediMed Ltd (IPD):製品パイプライン分析
    Summary ImpediMed Ltd (ImpediMed) is a manufacturer of bioimpedance devices with a focus on medical applications in the fluid status domain. It designs, manufactures and sells bioimpedance spectroscopy (BIS) devices for assessing lymphoedema and body composition. The major products of the company in …
  • Sanford Health-製薬・医療分野:企業M&A・提携分析
    Summary Sanford Health (Sanford) is a healthcare service provider that offers medical services. The center’s medical services include allergy and immunology, acupuncture, adult trauma, airmed, anesthesiology, breast health, behavioral health, pediatric care, bladder health, bleeding disorders, botox …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Medica Corp:企業の製品パイプライン分析2018
    Summary Medica Corp (Medica) is a medical device company that manufactures and markets in-vitro diagnostic blood testing analyzers. The company’s products comprise clinical chemistry analyzers, electrolyte analyzers, blood gas analyzers, and hematology analyzers, and OEM ISE modules. Medica’s produc …
  • Blue Cross (Asia-Pacific) Insurance Limited:企業の戦略・SWOT・財務情報
    Blue Cross (Asia-Pacific) Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Blue Cross (Asia-Pacific) Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Fagron NV (FAGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Fagron NV (Fagron), formerly Arseus NV is a pharmaceutical compounding solution provider. The company offers products such as raw materials, extracts and tinctures, flammable products, anesthesia, ointment bases, syrups, suspension media, triturations, phyto pharmaflore, medispend, capsicard …
  • Ceylon Electricity Board:電力:M&Aディール及び事業提携情報
    Summary Ceylon Electricity Board (CEB) is a power utility that generates, transmits and distributes electricity. The utility generates electricity using thermal, wind and hydro sources. It purchases power from the private IPPs to distribute across Sri Lanka. CEB’s services include implementation str …
  • Veryan Medical Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Veryan Medical Ltd (Veryan), a subsidiary of Veryan Holdings Ltd, is a medical device company that designs and develops vascular biomimetic stents. It develops BioMimics 3D stent, a peripheral self-expanding nickel-titanium alloy (Nitinol) stent with unique three-dimensional helical centreli …
  • Sandvik AB:企業の戦略・SWOT・財務情報
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Globalstar Inc (GSAT):企業の財務・戦略的SWOT分析
    Summary Globalstar Inc (Globalstar) is a technology company that offers satellite communication products and services. The company’s products include data and tracking products and phones and accessories, among others. Its phones and accessories comprise phones, extreme systems, sat-fi, docking kits …
  • EnBW Energie Baden-Wurttemberg AG (EBK)-エネルギー分野:企業M&A・提携分析
    Summary EnBW Energie Baden-Wuerttemberg AG (EnBW) is an integrated energy holding company that generates, procures, transmits and supplies electricity; and produces, transports and supplies gas through its subsidiaries. Its generation portfolio includes nuclear, coal, oil, gas, wind, and pumped stor …
  • CytoSorbents Corp (CTSO):企業の財務・戦略的SWOT分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …
  • HLL Lifecare Ltd:企業の製品パイプライン分析
    Summary HLL Lifecare Ltd (HLL) is a manufacturer of natural rubber latex condoms. The company offers products such as condoms, tubal rings, synthetic braided and coated absorbable suture, monofilament polydioxanone surgical suture, synthetic absorbable surgical suture, blood bank refrigerator, steri …
  • N V Nederlandse Gasunie:企業の戦略・SWOT・財務分析
    N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report Summary N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Rebiotix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company targets various disease conditions using drugs based on its microbiota restoration therapy platform. It lead product candidate RBX2660 is u …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆